GLP-1s in Perimenopause: Body Composition, Strength and HRT Questions

The number on the scale was the least interesting part

A familiar weight on the scale does not necessarily mean an unchanged body composition during the menopause transition. I would ask about strength, function and symptoms alongside weight rather than use an age or jeans size as a diagnosis. Those questions can make a GLP-1 appointment more useful than a discussion limited to pounds lost.

The research that matters here measures different things: fat and lean tissue, grip strength, weight and symptoms. I would keep those outcomes separate. An improvement in one cannot promise that everything else moves in the same direction, and a study in postmenopausal women may not answer a question about perimenopause.

What the transition actually does, and it is not what I assumed

The Study of Women's Health Across the Nation followed women through the menopause transition with DXA scans rather than bathroom scales, and the finding is genuinely counterintuitive: weight climbed in a straight line through premenopause and did not accelerate at the transition. What changed was the composition underneath it — the rate of fat gain doubled, and lean mass started to fall, with both continuing until about two years after the final period¹.

So the scale is not lying to you. It is answering a question you did not ask. Two women can gain the same four pounds a year and be having completely different decades.

For me, the useful reading question is what a weight change is made of and whether everyday function is being followed. I would ask how the clinician assesses that in routine care before deciding that an expensive body-composition measurement is necessary or that a bathroom scale tells the whole story.

Strength deserves its own place in follow-up

Here is the tension nobody handed me: perimenopause is already taking lean mass, and weight loss of any kind takes some too.

A 2026 observational study followed adults on semaglutide for twelve months alongside a lifestyle-only group. The semaglutide group lost substantially more weight — about eleven kilos more — and yes, their skeletal muscle mass fell, from 29.9 to 28.7 kg, with fat-free mass down from 53.8 to 52.7 kg. But the same study measured grip strength, and absolute strength was preserved in both groups; relative strength actually improved on semaglutide².

I want to be careful with that, because it is a small single-center retrospective study using bioimpedance, not a trial. It is a reason to pay attention, not a reason to panic, and not a reason to skip the medication.

I would bring resistance exercise, adequate intake and functional goals into the care discussion rather than wait until the scale reaches a target. The observational study does not prescribe an exercise routine for a particular person. I would ask what activity fits existing injuries, energy and experience, and what changes in strength or function should prompt a review.

If you are on HRT, this is the bit I would want flagged

For someone using hormone therapy, I would bring the exact formulation, route and symptom history to the prescribing visit. An oral tablet and a patch are different routes; a concern about one is not automatically evidence of a problem with the other.

There is a published case report of a fifty-one-year-old woman on oral estrogen whose hot flashes and mood changes got noticeably worse during her semaglutide dose increases. The proposed explanation is that GLP-1s slow gastric emptying, which can temporarily reduce how much of an oral dose gets absorbed — and when her titration was slowed, the symptoms resolved³.

One patient. One report. A hypothesis, not a finding, and the author says so plainly.

The report suggests a timing question worth raising: did symptoms change during semaglutide initiation or escalation? It does not establish that oral estrogen absorption is reduced in everyone or that a patch is a necessary workaround. If hot flashes or mood symptoms worsen, tell the clinician managing hormone therapy. I would not change the dose, route or GLP-1 schedule independently based on one case.

A recent review discusses GLP-1 treatment and sexual function in midlife women, but emphasizes that direct clinical evidence remains limited⁴. I would read that as a reason to ask about symptoms and follow-up, not as proof of a predictable benefit beyond weight.

One more study I'd want flagged if you're on hormone therapy. Among postmenopausal women on semaglutide, the small group also using hormone therapy lost more weight on average than the women who weren't⁵. It was a look back through records, with only sixteen women on hormones, so it is a question rather than an answer. I went through it, and what menopause specialists now say about it, in GLP-1s after menopause.

What I actually ask about now

Three questions I would bring to the appointment:

• What is happening to my lean mass, and how would we know — is anyone measuring, or are we both watching a scale? Same question for my bones, which I wrote up in GLP-1s and bone density.
• If I use oral HRT and symptoms change, what information should I record and who should review it before any dosing change?
• What does maintenance look like for someone whose body is changing underneath the medication anyway?

Keep function and symptoms beside the weight record

I would judge a care plan by whether it follows the questions that matter to the person using it: strength, intake, symptoms, tolerability and sustainable treatment. A scale can contribute without becoming the only outcome. My notes would include changes worth discussing, rather than a promised version of what a woman in her forties should experience.

Perimenopause does not mean pregnancy is impossible. GLP-1 treatment and pregnancy planning need a clinician’s advice, and breastfeeding decisions depend on the exact medicine, formulation and infant. I would raise those questions before treatment rather than assume midlife hormone care settles them.